Redeye sammanfattar att riskerna minskar:
The growing body of clinical and mechanistic evidence generated through BEXMAB provides an increasingly solid foundation for this transition into randomized development and, in our view, incrementally de-risks the broader bexmarilimab
programme.
Bilderna från presentationen har tagits med väl i rapporten.
Redeye EHA 2026.pdf (2,5 Mt)